MetaCap

Eocene (EOCN) vs PharmaCyte Biotech (PMCB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.

Summary

PharmaCyte Biotech is the larger company by market cap ($4.3 million vs $3.7 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EOCN+4.69%PMCB-2.02%
+5%+1%-2%
Oct 7, 20261 yearOct 8, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EOCN versus PMCB key metrics
MetricEOCNPMCB
Share price$3.46$0.3975
Market cap$3.70M$4.27M
1-day change-4.40%-1.58%
EPS (TTM)$-15.21$-2.31
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$12.80$1.51
52-week low$3.12$0.3339
Distance from 52-week high-72.96%-73.68%
Analyst consensusnone—
Average volume59.85K205.72K
Shares outstanding1.07M10.74M
Employees32
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Eocene

EOCN stock →

Eocene Ltd. a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications.

Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees

About PharmaCyte Biotech

PMCB stock →

PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2 employees

EOCN vs PMCB FAQ

Which is bigger, Eocene or PharmaCyte Biotech?

PharmaCyte Biotech (PMCB) is larger, with a market capitalization of $4.27M compared with $3.70M for Eocene (EOCN).

Are Eocene and PharmaCyte Biotech in the same industry?

Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Eocene and Biotechnology: Biological Products (No Diagnostic Substances) for PharmaCyte Biotech.

More comparisons